PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Chemical stem cell signature predicts treatment response for acute myeloid leukemia

2014-02-03
(Press-News.org) Contact information: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Chemical stem cell signature predicts treatment response for acute myeloid leukemia February 3, 2014 — (Bronx, NY) — Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found a chemical "signature" in blood-forming stem cells that predicts whether patients with acute myeloid leukemia (AML) will respond to chemotherapy.

The findings are based on data from nearly 700 AML patients. If validated in clinical trials, the signature would help physicians better identify which AML patients would benefit from chemotherapy and which patients have a prognosis so grave that they may be candidates for more aggressive treatments such as bone-marrow transplantation. The paper was published today in the online edition of the Journal of Clinical Investigation.

Sparing Patients from Debilitating Side Effects According to the American Cancer Society, AML accounts for nearly one-third of all new leukemia cases each year. In 2013, more than 10,000 patients died of AML.

"AML is a disease in which fewer than 30 percent of patients are cured," said co-senior author Ulrich Steidl, M.D., Ph.D., associate professor of cell biology and of medicine and the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research at Einstein and associate chair for translational research in oncology at Montefiore. "Ideally, we would like to increase that cure rate. But in the meantime, it would help if we could identify who won't benefit from standard treatment, so we can spare them the debilitating effects of chemotherapy and get them into clinical trials for experimental therapies that might be more effective."

Analyzing Methylation Patterns The Einstein study focused on so-called epigenetic "marks" – chemical changes in DNA that turn genes on or off. The researchers focused on one common epigenetic process known as methylation, in which methyl (CH3) groups attach in various patterns to the genes of human cells. Researchers have known that aberrations in the methylation of hematopoietic, or blood-forming, stem cells (HSCs) can prevent them from differentiating into mature blood cells, leading to AML.

Dr. Steidl suspected that comparing how closely the DNA methylation patterns in the cancerous white blood cells of AML patients resembled the patterns found in healthy individuals' HSCs might foretell the patients' response to treatment. To find out, he and his colleagues at the Albert Einstein Cancer Center carried out a novel DNA methylation analysis on 561 genes in healthy HSCs at various stages of differentiation. This new technique, developed by co-senior author Amit Verma, M.D., allows researchers, for the first time, to study DNA methylation of cells such as HSCs that can be found only in small quantities. Dr. Verma is associate professor of medicine and of developmental & molecular biology at Einstein and director, hematologic malignancies at the Montefiore Einstein Center for Cancer Care.

The researchers first analyzed HSCs from three healthy individuals to determine normal methylation patterns. They found that in the HSCs of healthy people, most DNA cytosines (one of four main components of DNA) are methylated. They noted that where demethylation (removal of methyl groups) occurs, it's limited mainly to one particular stage of HSC differentiation.

Using Epigenetic Signatures to Predict Survival The researchers hypothesized that by comparing the "epigenetic signature" of healthy people's HSCs with that of AML patients' cancerous white blood cells, they could predict survival of AML patients. In other words, patients with a methylation pattern resembling that of healthy people's HSCs (i.e., a "low score") would be more likely to live longer – and therefore benefit more from chemotherapy – than patients with a high score.

The researchers then tested their scoring method using data on 688 AML patients in three different clinical trials, In each of these groups, patients with low scores (methylation patterns similar to normal HSCs) had approximately twice the median survival time of patients with high scores. "Our epigenetic stem cell signature was clearly superior to similar tests that have been used," said Dr. Steidl.

Dr. Steidl and his colleagues are now studying the genes that are included in the aberrant signatures to determine if they play a role in causing AML.

### The paper is titled "HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia." The other Einstein contributors are Boris Bartholdy, Ph.D., Maximilian Christopeit, Ph.D., Britta Will, Ph.D., Yongkai Mo, Ph.D., Laura Barreyro, Ph.D., Yiting Yu, Ph.D., Tushar D. Bhagat, Ph.D., Ujunwa C. Okoye-Okafor, M.S., Tihomira I. Todorova, B. Sc., and John Greally, M.B.B.Ch., Ph.D. Additional contributors are Ross Levine, at Memorial-Sloan Kettering Cancer Center, New York, NY, and Ari Melnick at Weill Cornell Medical College, New York, NY.

The study was supported by a grant from the Deutsche Forschungsgemeinschaft (CH945/1-1), a Howard Temin Award of the National Cancer Institute (CA131503), and a NYSTEM research grant (C024306).

The authors report no conflicts of interest.

About Albert Einstein College of Medicine of Yeshiva University Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. During the 2013-2014 academic year, Einstein is home to 734 M.D. students, 236 Ph.D. students, 106 students in the combined M.D./Ph.D. program, and 353 postdoctoral research fellows. The College of Medicine has more than 2,000 full-time faculty members located on the main campus and at its clinical affiliates. In 2013, Einstein received more than $155 million in awards from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore Medical Center, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Through its extensive affiliation network involving Montefiore, Jacobi Medical Center–Einstein's founding hospital, and five other hospital systems in the Bronx, Manhattan, Long Island and Brooklyn, Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States. For more information, please visit http://www.einstein.yu.edu and follow us on Twitter @EinsteinMed. About Montefiore Medical Center As the University Hospital for Albert Einstein College of Medicine, Montefiore is a premier academic medical center nationally renowned for its clinical excellence, scientific discovery and commitment to its community. Recognized among the top hospitals nationally and regionally by U.S. News & World Report, Montefiore provides compassionate, patient- and family-centered care and educates the healthcare professionals of tomorrow. The Children's Hospital at Montefiore is consistently named in U.S. News' "America's Best Children's Hospitals." With four hospitals, 1,491 beds and 90,000 annual admissions, Montefiore is an integrated health system seamlessly linked by advanced technology. State-of-the-art primary and specialty care is provided through a network of more than 130 locations across the region, including the largest school health program in the nation and a home health program. Montefiore's partnership with Einstein advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. The medical center derives its inspiration for excellence from its patients and community, and continues to be on the frontlines of developing innovative approaches to care. For more information please visit http://www.montefiore.org and http://www.montekids.org. Follow us on Twitter; like us on Facebook; view us on YouTube.


ELSE PRESS RELEASES FROM THIS DATE:

Study finds intervention leads to reduction of C-sections and neonatal morbidities

2014-02-03
In a study to be presented on Feb. 6 in an oral plenary session at 8 a.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting™, in ...

Study's results encourage expectant monitoring for women with hypertension

2014-02-03
In a study to be presented on Feb. 6 at 8:15 a.m. CST, at the Society for Maternal-Fetal ...

Study finds NIPT detects more than 80 percent of chromosomal abnormalities

2014-02-03
In a study to be presented on Feb. 6 at 9 a.m. CST, at the Society for Maternal-Fetal ...

Study associates gene with cerebral palsy and death in very preterm babies

2014-02-03
In a study to be presented on Feb. 6 at 2:45 p.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting™, in New Orleans, researchers will report ...

Study finds cervicovaginal microbiota differs in women to have preterm birth

2014-02-03
In a study to be presented on Feb. 6 at 3:15 p.m. CST, at the Society for Maternal-Fetal ...

Researchers identify new approach to personalize prevention of preterm birth

2014-02-03
New research findings may soon help doctors personalize preterm birth prevention treatments by identifying which women at higher ...

Study suggests women 35+ are at decreased risk to have anatomically abnormal child

2014-02-03
In a study to be presented on Feb. 6 at 3 p.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting™, in New Orleans, researchers will ...

Study correlates neonatal and early childhood outcomes with preterm birth

2014-02-03
In a study to be presented on Feb. 6 at 3:15 p.m. CST, at the Society for ...

Patient-controlled analgesia not as effective as epidural for labor pain

2014-02-03
In a study to be presented on Feb. 7 at 1:30 p.m. ...

Study finds increasing trend in home birth neonatal mortality rates

2014-02-03
In a study to be presented on Feb. 7 at 2:15 p.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting™, in New Orleans, researchers will report that ...

LAST 30 PRESS RELEASES:

Fig trees convert atmospheric CO2 to stone

Intra-arterial tenecteplase for acute stroke after successful endovascular therapy

Study reveals beneficial microbes that can sustain yields in unfertilized fields

Robotic probe quickly measures key properties of new materials

Climate change cuts milk production, even when farmers cool their cows

Frozen, but not sealed: Arctic Ocean remained open to life during ice ages

Some like it cold: Cryorhodopsins

Demystifying gut bacteria with AI

Human wellbeing on a finite planet towards 2100: new study shows humanity at a crossroads

Unlocking the hidden biodiversity of Europe’s villages

Planned hydrogen refuelling stations may lead to millions of euros in yearly losses

Planned C-sections increase the risk of certain childhood cancers

Adults who have survived childhood cancer are at increased risk of severe COVID-19

Drones reveal extreme coral mortality after bleaching

New genetic finding uncovers hidden cause of arsenic resistance in acute promyelocytic leukemia

Native habitats hold the key to the much-loved smashed avocado’s future

Using lightning to make ammonia out of thin air

Machine learning potential-driven insights into pH-dependent CO₂ reduction

Physician associates provide safe care for diagnosed patients when directly supervised by a doctor

How game-play with robots can bring out their human side

Asthma: patient expectations influence the course of the disease

UNM physician tests drug that causes nerve tissue to emit light, enabling faster, safer surgery

New study identifies EMP1 as a key driver of pancreatic cancer progression and poor prognosis

XPR1 identified as a key regulator of ovarian cancer growth through autophagy and immune evasion

Flexible, eco-friendly electronic plastic for wearable tech, sensors

Can the Large Hadron Collider snap string theory?

Stuckeman professor’s new book explores ‘socially sustainable’ architecture

Synthetic DNA nanoparticles for gene therapy

New model to find treatments for an aggressive blood cancer

Special issue of Journal of Intensive Medicine analyzes non-invasive respiratory support

[Press-News.org] Chemical stem cell signature predicts treatment response for acute myeloid leukemia